Streetbeat News

Products Services

GOOG

GOOGL

MSFT

WFC

Google and Microsoft face backlash for including ads in AI trials without opt-out options, raising concerns among advertisers about marketing budgets and control over ad placements. Wells Fargo temporarily pulled its ad spending from Microsoft.

Portfolio Pulse from Anusuya Lahiri

June 08, 2023 | 12:03 pm

SKIL

Skillsoft has launched a new ChatGPT Learning Journey course, designed to help learners develop their conversational AI skills using OpenAI's ChatGPT technology.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 12:03 pm

UNVR

Univar Solutions has expanded its specialty pharmaceutical and nutraceutical ingredient portfolios by adding Grace SYLOID FP Silica for the majority of Europe. This move is expected to strengthen Univar's position in the market.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 12:03 pm

OCEA

Ocean Biomedical has been granted a patent for its malaria vaccine in Brazil, potentially expanding its market and revenue opportunities.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 12:02 pm

EADSY

Airbus SE reported a 34% YoY increase in May deliveries, with 63 airplanes delivered to 36 customers. The company has delivered a total of 244 airplanes to 70 customers this year. Airbus also received a firm order for 43 helicopters from Air Corporate in Italy.

Portfolio Pulse from Nabaparna Bhattacharya

June 08, 2023 | 11:59 am

FDMT

4D Molecular Therapeutics (NASDAQ:FDMT) announced positive interim data from the 4D-710 Phase 1/2 AEROW trial for cystic fibrosis lung disease. The aerosol delivery procedure was well tolerated, and biomarker analyses showed widespread CFTR expression. The company also recently released interim clinical data for wet age-related macular degeneration.

Portfolio Pulse from Vandana Singh

June 08, 2023 | 11:53 am

RPTX

Repare Therapeutics reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib in advanced solid tumors. Preliminary antitumor activity was observed, and early clinical combination insights demonstrated greater antitumor activity with lunresertib plus camonsertib. The tolerability profile of lunresertib monotherapy appears favorable.

Portfolio Pulse from Vandana Singh

June 08, 2023 | 11:49 am

CYBN

Cybin expects topline clinical data readouts in late Q3 2023, including Phase 2a efficacy data for CYB003 and Phase 1 data for CYB004. The company believes this will provide the necessary capital to complete clinical milestones and focus on clinical execution.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:44 am

ACON

Aclarion announced that their Nociscan cost-effectiveness abstract was presented at the ISASS Annual Meeting, showing that Nociscan statistically dominates provocative discography (PD) in terms of cost and effectiveness. The study was performed at CDMI through an NSF grant sponsored by Aclarion.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:37 am

AXON

Axon announced that CHRISTUS Health will equip its hospital security officers with Axon Body 3 cameras. This partnership aims to enhance safety and transparency in healthcare facilities.

Portfolio Pulse from Benzinga Newsdesk

June 08, 2023 | 11:37 am